The foundation of Glutagen’s innovation
Glutagen is a biopharmaceutical company based in Melbourne, Australia. With evidence-based innovation at our core, we specialise in the development and commercialisation of novel therapeutics to enhance and support the health, wellbeing and lifestyle of the community with gluten related disorders.
By understanding the intricacies and challenges of living a gluten free lifestyle and coupling this with clinical evidence and expert research in enzyme therapy, Glutagen provides practical solutions with the highest quality products to empower the gluten free community.
The values we stand for
Our leadership team
Glutagen is led by a passionate team united in their mission to advance gluten science through innovative research and technology. Together, we are building strong connections, fostering understanding, and facilitating education within our community.
Our medical advisory committee
Comprising of renowned experts and key opinion leaders in gluten-related disorders and inflammatory diseases, our committee guide our strategic direction on research, technology development, and improving the wellbeing of individuals with gluten-related disorders.
Collaborate and make a global impact with Glutagen
The foundation of our understanding
Glutagen is the culmination of decades of Australian clinical and scientific research. The early work by Professor Hugh Cornell in illustrating the biochemical composition of gluten has been instrumental for today’s understanding of gluten’s toxicity in gluten-related disorders.
The genesis of an innovative idea
Professor Hugh Cornell, a former Professor of Biological Chemistry at the RMIT University and Dr. Teodor Stelmasiak a veterinary pathologist with over 25 years of experience in pharmaceutical research, hypothesised a novel concept: delivering the right enzyme to the gastrointestinal tract prior to the consumption of foods could complete the digestion of the toxic and immunogenic gluten peptides and protect patients against the effects caused by inadvertent gluten ingestion.
The birth of Glutagen
In 2001, Dr Stelmasiak founded Glutagen, propelled by the discovery that caricain is capable of digesting gluten, promising a significant breakthrough in the management of gluten-related disorders.
Research and trials
Caricain was extensively researched in-vitro and in randomised placebo controlled clinical trials exploring the effect of caricain supplementation on symptoms and biomarkers of gluten related disorders. These trials demonstrated that enzyme therapy with caricain was successful at protecting participants against the effects of a daily gluten challenge.
An honourable recognition
Prof. Cornell was awarded a Medal of the Order of Australia (OAM) in 2021 for his contributions to biochemical research in enzyme therapy and tertiary education.
A revolutionary market launch
Launched initially through a direct online sales pilot, the enteric coated tablets containing Caricain, quickly obtained valuable consumer and product insights that shaping its offer. Now successfully distributed in more than 3,400 pharmacies Australia-wide, the product has become one of the most successful launches in the Australian consumer healthcare product market, changing lives for the better through a concentrated effort on education for both healthcare professionals and consumers.